Excellence in Care: New Drugs Released in 2006

Transcription

1 Excellence in Care: New Drugs Released in 2006 Renee Acosta, R.Ph INDEPENDENT STUDY Health Professions Institute for Continuing Education Austin Community College

2 The Austin Community College Health Professions Institute, Continuing Education 5930 Middle Fiskville Road, Austin, TX INDEPENDENT STUDY: Excellence in Care: New Drugs Released in 2006 Description and Purpose: Renee Acosta, RPh, appears with Elizabeth Huss RN, BSN, coordinator with the Health Professions Institute of Austin Community College, to discuss new medications released in 2006 and includes information on mechanism of action, classification, indication, dosing/administration, and special considerations. Ms. Acosta is an instructor for the School of Pharmacy at the University of Texas at Austin and developer of the Pharmacy Technician Program at Austin Community College as well as a published author. The purpose of this activity is to enrich the participant s contribution to quality healthcare and the pursuit of professional career goals by providing updated information on the use, interaction concerns, and precautions needed regarding new medications approved by the FDA and released in This offering is a self-paced learning activity developed to meet the individual needs of nurses, social workers, and emergency medical services personnel requiring continuing education for relicensure. Goals and Objectives: Upon completion of this activity, the student will be able to: 1. List three (3) new drugs released in 2006 that were approved via the priority review process (not the standard FDA review). 2. Describe the four (4) new drugs released in 2006 including their mechanism of action, route of administration, and any special considerations. 3. Identify four (4) new biologic agents released in Discuss three (3) drugs that are either new in 2006 or recently released in the last few years that nurses should be aware of and familiar with. Requirements for Successful Completion: The packet you have received contains a pre-test, DVD, post-test and a program evaluation. To successfully complete this activity and earn continuing education the participant must: 1. Complete the pre-test 2. View the DVD 3. Complete the post-test (score an 80 or more) 4. And, complete the evaluation NOTE: Following the viewing of the DVD and completing the accompanying documents, questions may be addressed by contacting Elizabeth or eahuss@austincc.edu Submit all of the documents (pre/post-test, evaluation) along with your completed Registration Form (check or credit card), and payment to:

3 Austin Community College Health Professions Institute Attn: Online Nursing Videos 5930 Middle Fiskville Rd. Austin, TX Fax: Within two business weeks from receipt of your material at ACC, your certificate of completion will be available (to be mailed, fax, or picked up at the above address your choice). Upon successful completion participants will be awarded a certificate of successful completion worth 2.0 contact hours. Austin Community College is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center s Commission on Accreditation. Contact hours for programs applicable to social work are approved for CEU s by the Texas State Board of Social Worker Examiners. This program is worth 2.0 contact hours or 0.2 continuing education units (CEU s). Continuing education for Emergency Medical Personnel is approved by the Texas Department of State Health Services. This program is worth 2.0 TDH (P) contact hours. Disclosure to Attendees: The presenters and planning committee members for this offering have completed Conflict of Interest forms and it has been determined that no conflict of interest exists or has been indentified in relation to this offering. Commercial Support: This offering has not received any commercial support. Non-endorsement of products: The discussion of generic or brand name items or medications does not constitute endorsement by the American Nurses Credential Center s Commission on Accreditation (ANCC), the Texas Nurses Association (TNA) or Austin Community College. Off-Label Use: Off-label use of medications refers to the prescribing of medications to treat a condition for which the medication has not been approved by the Food and Drug Administration. Medications presented in this activity will only be discussed in the context of their Federal Drug Administration (FDA) approval. This Educational Activity Expires: May 31, 2013

4 Printed Name: Date: Instructions: Complete this pre-test PRIOR to watching the video. Choose the best answer by circling the letter corresponding to your choice. Submit this pre-test only with your post-test and completed evaluation to: Austin Community College Health Professions Institute Attn: Online Nursing Videos 5930 Middle Fiskville Rd. Austin, TX Fax: Pre-Test: New Drugs Released in The following drug was released in 2006 as an over-the-counter topical sunscreen: a. Darunavir (Prezista) b. Andulafungin (Eraxis) c. Avobenzone/Ecamsule/Octocrylene (Anthelios SX) d. None of the above 2. The following are true regarding the use of sunscreen EXCEPT: a. Sunscreen does not need to be reapplied after the initial application. b. Sunscreen should be applied daily not just when planning to be in the sun. c. Sunscreen needs to be reapplied throughout the day. d. b and c are true 3. The following drug was released in 2006, contains 3 medications combined into one capsule, and is indicated for the treatment of Helicobacter pylori: a. Avobenzone/Ecamsule/Octocrylene (Anthelios SX) b. Biskalcitrate/Metronidazole/Tetracycline (Pylera) c. Andulafungin (Eraxis) d. None of the above 4. Individuals taking Biskalcitrate/Metronidazole/Tetracycline (Pylera) need to be educated regarding which of the following: a. This drug increases sensitivity to the sun. Avoiding the sun, wearing sunscreen and protective clothing is recommended. b. Do not take right before bed c. Do not take calcium, iron, or zinc 2 hours after last dose or 4 hours before next dose. d. All of the above

5 5. This drug requires activation in the nasal mucosa and is approved for the treatment of rhinitis: a. Ciclesonide (Omnaris) b. Lubiprostone (Amitiza) c. Sitagliptin phosphate (Januvia) d. Vorinostat (Zolinza) 6. This drug cannot be administered to individuals with a known sulfa allergy: a. Dasatinib (Sprycel) b. Decitabine (Dacogen) c. Darunavir (Prezista) d. Sunitinib (Sutent) 7. This drug is derived from green tea leaves: a. Kunecatechins (Veregen) b. Paliperidone (Invega) c. Posaconazole (Noxafil) d. Ranolazine (Ranexa) 8. The following drug is indicated for schizophrenia and is released over a 24 hour period (OROS extended-release technology): a. Lubiprostone (Amitiza) b. Posaconazole (Noxafil) c. Kunecatechins (Veregen) d. Paliperidone (Invega) 9. The use of OROS extended-release technology in drug delivery helps with medication compliance. a. True b. False 10. Posaconazole (Noxafil) is indicated for: a. The treatment of schizophrenia b. The treatment of chronic stable angina c. Aid to smoking cessation d. Prevention of aspergillus and candida in the immunocompromised 11. The following are all true regarding the administration of Sitagliptin phosphate (Januvia) EXCEPT: a. This drug interacts with digoxin and therefore dig levels need to be monitored closely b. Dosage is adjusted for creatnine clearance c. It is administered IV only d. It is indicated for the treatment of Type 2 Diabetes

6 12. This new drug released in 2006 is indicated to aid in smoking cessation: a. Telbivudine (Tyzeka) b. Varenicline (Chantix) c. Vorinostat (Zolinza) d. Ciclesonide (Omnaris) 13. This drug is an anti-cancer drug administered orally via capsules and indicated for the treatment of recurrent T-cell lymphoma: a. Vorinostat (Zolinza) b. Varenicline (Chantix) c. Telbivudine (Tyzeka) d. Sunitinib (Sutent) 14. The following are biologic agents released in 2006: a. Chantix, Eraxis, Myozyme, Elaprase b. Vectibix, Lucentis, Chantix, Eraxis c. Myozyme, Lucentis, Elaprase, Vectibix d. Gardasil, Myozyme, Caduet, Eraxis 15. This drug is used for the treatment of osteoporosis and is administered IV: a. Gardasil b. Exubera c. Caduet d. Boniva

7 Written: I. Pre-Test Excellence in Care: New Drugs Released in 2006 Program Outline DVD Presentation: II. New Drugs Released in 2006 A. New Drug Applications Approved B. New Drugs of 2006 Andulafungin (Eraxis) Avobenzone/Ecamsule/Octocrylene (Anthelios SX) Biskalcitrate/Metronidazole/Tetracycline (Pylera) Ciclesonide (Omnaris) Darunavir (Prezista) Dasatinib (Sprycel) Decitabine (Dacogen) Kunecatechins (Veregen) Lubiprostone (Amitiza) Paliperidone (Invega) Posaconazole (Noxafil) Ranolazine (Ranexa) Rasagiline Mesylate (Azilect) Sitagliptin phosphate (Januvia) Sunitinib (Sutent) Telbivudine (Tyzeka) Varenicline (Chantix) Vorinostat (Zolinza) III. New Biologics Aglucosidase (Myozyme) Idursulfase (Elaprase) Panitumumab (Vectibix) Ranibizumab (Lucentis) IV. Hot Drugs for Nursing Gardasil Exubera Caduet Atripla Boniva Written: VI. Post-Test VII. Evaluation

8 Evaluation Title of Education Activity: Excellence in Care: New Drugs Released in 2006 Location: DVD Video Format Date: Participants check out and complete on own time Purpose of this activity: The purpose of this activity is to enrich the participant s contribution to quality healthcare and the pursuit of professional career goals by providing updated information on the use, interaction concerns, and precautions needed regarding new medications approved by the FDA and released in Directions/Instructions: Please complete this evaluation questionnaire. Your anonymous responses will be used to revise this activity and to plan future educational activities. Circle the number that best fits your evaluation of this activity. 1 = Not at all 2 = Somewhat 3 = Almost completely 4 = Completely 1. Rate your achievement of these objectives: a. List three (3) new drugs released in 2006 that were approved via the priority review process (not the standard FDA review). b. Describe four (4) new drugs released in 2006 including their mechanism of action, route of administration, and any special considerations. c. Identify four (4) new biologic agents released in d. Discuss three (3) drugs that are either new in 2006 or recently released in the last few years that nurses should be aware of and familiar with. 2. Rate the effectiveness of the teaching/learning resources? Please evaluate the guest speaker- Renee Acosta, RPh a. Knowledge and currency of topic b. Ability to make points clear c. Ability to apply content to practice Please evaluate the moderator- Elizabeth Huss RN, BSN a. Guides the discussion b. Asks pertinent questions c. Fosters clarification of presented information Were the objectives relevant to the overall purpose? (see above)

9 5. How long (in minutes) did it take you to complete the entire activity (including taking the pretest, watching the video, taking the post-test, and completing this evaluation tool)? Minutes 6. List two (2) ways you will integrate what you learned in this activity into your practice and/or employment environment. 8. The following were disclosed prior to the beginning of this activity either in writing or verbally? a. Requirements for successful completion Yes No b. Conflicts of Interest Yes No c. Commercial Support Yes No d. Non-endorsement of Products Yes No e. Off-label Use Yes No 9. Did you, as a participant, notice any bias that was not previously disclosed in this presentation? Yes No If Yes, please describe who was biased and how. 10. Comments: If you answered (1) to any of the above, please comment. 11. Please list any suggestions or topics for future programming.

10 Printed Name: Date: Instructions: Complete this post-test AFTER viewing the video. Choose the best answer by circling the letter corresponding to your choice. Submit this pre-test only with your post-test and completed evaluation to: Austin Community College Health Professions Institute Attn: Online Nursing Videos 5930 Middle Fiskville Rd. Austin, TX Fax: Post-test: New Drugs Released in The following drug was released in 2006 as an over-the-counter topical sunscreen: a. Darunavir (Prezista) b. Andulafungin (Eraxis) c. Avobenzone/Ecamsule/Octocrylene (Anthelios SX) d. None of the above 2. The following are true regarding the use of sunscreen EXCEPT: a. Sunscreen does not need to be reapplied after the initial application. b. Sunscreen should be applied daily not just when planning to be in the sun. c. Sunscreen needs to be reapplied throughout the day. d. b and c are true 3. The following drug was released in 2006, contains 3 medications combined into one capsule, and is indicated for the treatment of Helicobacter pylori: a. Avobenzone/Ecamsule/Octocrylene (Anthelios SX) b. Biskalcitrate/Metronidazole/Tetracycline (Pylera) c. Andulafungin (Eraxis) d. None of the above 4. Individuals taking Biskalcitrate/Metronidazole/Tetracycline (Pylera) need to be educated regarding which of the following: a. This drug increases sensitivity to the sun. Avoiding the sun, wearing sunscreen and protective clothing is recommended. b. Do not take right before bed c. Do not take calcium, iron, or zinc 2 hours after last dose or 4 hours before next dose. d. All of the above

11 5. This drug requires activation in the nasal mucosa and is approved for the treatment of rhinitis: a. Ciclesonide (Omnaris) b. Lubiprostone (Amitiza) c. Sitagliptin phosphate (Januvia) d. Vorinostat (Zolinza) 6. This drug cannot be administered to individuals with a known sulfa allergy: a. Dasatinib (Sprycel) b. Decitabine (Dacogen) c. Darunavir (Prezista) d. Sunitinib (Sutent) 7. This drug is derived from green tea leaves: a. Kunecatechins (Veregen) b. Paliperidone (Invega) c. Posaconazole (Noxafil) d. Ranolazine (Ranexa) 8. The following drug is indicated for schizophrenia and is released over a 24 hour period (OROS extended-release technology): a. Lubiprostone (Amitiza) b. Posaconazole (Noxafil) c. Kunecatechins (Veregen) d. Paliperidone (Invega) 9. The use of OROS extended-release technology in drug delivery helps with medication compliance. a. True b. False 10. Posaconazole (Noxafil) is indicated for: a. The treatment of schizophrenia b. The treatment of chronic stable angina c. Aid to smoking cessation d. Prevention of aspergillus and candida in the immunocompromised 11. The following are all true regarding the administration of Sitagliptin phosphate (Januvia) EXCEPT: a. This drug interacts with digoxin and therefore dig levels need to be monitored closely b. Dosage is adjusted for creatnine clearance c. It is administered IV only d. It is indicated for the treatment of Type 2 Diabetes

12 12. This new drug released in 2006 is indicated to aid in smoking cessation: a. Telbivudine (Tyzeka) b. Varenicline (Chantix) c. Vorinostat (Zolinza) d. Ciclesonide (Omnaris) 13. This drug is an anti-cancer drug administered orally via capsules and indicated for the treatment of recurrent T-cell lymphoma: a. Vorinostat (Zolinza) b. Varenicline (Chantix) c. Telbivudine (Tyzeka) d. Sunitinib (Sutent) 14. The following are biologic agents released in 2006: a. Chantix, Eraxis, Myozyme, Elaprase b. Vectibix, Lucentis, Chantix, Eraxis c. Myozyme, Lucentis, Elaprase, Vectibix d. Gardisil, Myozyme, Caduet, Eraxis 15. This drug is used for the treatment of osteoporosis and is administered IV: a. Gardasil b. Exubera c. Caduet d. Boniva